| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The compound targets FABP1 (liver), FABP4 (adipose/macrophage) with IC₅0 of 0.65 microM and 1.08 microM, respectively. It also activates PPARalpha (EC₅0 9.19 microM), PPARgamma (EC₅0 2.20 microM), and PPARdelta (EC₅0 1.58 microM). This dual mechanism reduces lipid accumulation and inflammation.
|
|---|---|
| ln Vitro |
In vitro, it inhibits FABP4 in a fluorescence polarization assay (IC₅0 1.08 microM) and activates PPARgamma in a luciferase reporter assay (EC₅0 2.20 microM). In HepG2 cells, it reduces lipid droplet accumulation without cytotoxicity up to 30 microM. It downregulates pro-inflammatory genes (TNF-alpha, IL-6) in macrophages. Its metabolic switch activity is confirmed by increased oxygen consumption rate.
|
| ln Vivo |
In a WD + CCl4-induced MASH mouse model, oral administration (10-60 mg/kg) for 4 weeks dose-dependently reduces steatosis, inflammation, and fibrosis. It decreases serum ALT, AST, and liver hydroxyproline content. The compound is effective at 30 mg/kg and is better than rosiglitazone in some parameters. It is well-tolerated with no body weight loss.
|
| Enzyme Assay |
In vitro FABP4 fluorescence polarization assay: Incubate recombinant human FABP4 (100 nM) with fluorescent probe (10 nM) and test compound (0.01-100 microM) in assay buffer for 1 h at 25degC. Measure FP at 485/535 nm. IC₅0 is calculated. For PPARgamma transactivation: Transfect HEK293 cells with PPARgamma expression and PPRE-luciferase reporters. Treat with compound (0.1-100 microM) for 24 h, then measure luciferase activity. EC₅0 is determined.
|
| Cell Assay |
In vitro MTT assay: Seed HepG2 cells in 96-well plates, treat with compound (0.1-100 microM) for 48 h, add MTT, read at 570 nm. IC₅0 >50 microM. For anti-inflammatory activity: Treat RAW264.7 macrophages with compound (1-30 microM) for 2 h, then stimulate with LPS (1 microg/mL) for 24 h. Measure TNF-alpha and IL-6 by ELISA; compound reduces cytokine levels.
|
| Animal Protocol |
In vivo MASH model: C57BL/6J mice fed Western diet for 20 weeks and injected with CCl4 (1.5 mL/kg, i.p., twice weekly) for final 4 weeks. Compound is given orally (0, 10, 30, 60 mg/kg/day) for 4 weeks. Assess liver histology (H&E, Sirius Red), serum ALT/AST, liver triglycerides, and hydroxyproline. Positive control: rosiglitazone (10 mg/kg).
|
| ADME/Pharmacokinetics |
The compound has good oral bioavailability (>30%) in rodents. After oral administration, Tmax is 1-2 h, plasma half-life is 2-4 h. Volume of distribution is moderate (1-2 L/kg). It is likely metabolized by CYP3A4. The therapeutic doses (30-60 mg/kg) achieve micromolar plasma concentrations, matching its in vitro EC₅0 values.
|
| Toxicity/Toxicokinetics |
In the 28-day MASH study, no significant toxicity or body weight loss was observed at doses up to 60 mg/kg. As a PPARgamma agonist, potential class effects (edema, weight gain) may occur at higher doses. It is not genotoxic (no structural alerts). For impurity qualification, routine control at 0.15% is acceptable.
|
| References | |
| Additional Infomation |
(E/Z)-ABP/PPAR modulator 1 is a multi-target drug candidate discovered by researchers and reported in the European Journal of Medicinal Chemistry. It represents a novel strategy for MASH by simultaneously targeting FABP and PPAR pathways. The E/Z isomer mixture is supplied as a solid powder, stored at -20degC, soluble in DMSO.
|
| Molecular Formula |
C33H39NO7
|
|---|---|
| Molecular Weight |
561.67
|
| Related CAS # |
ABP/PPAR modulator 1
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~178.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.45 mM)(saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one)),clear solution.
For example, if 1 mL of working solution is to be prepared, you can Add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix thoroughly. Then add 50 μL of Tween-80 to the above system and mix thoroughly. Finally, add 450 μL of physiological saline to bring the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in ddH₂O and bring the volume to 100 mL to obtain a clear and transparent physiological saline solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7804 mL | 8.9020 mL | 17.8040 mL | |
| 5 mM | 0.3561 mL | 1.7804 mL | 3.5608 mL | |
| 10 mM | 0.1780 mL | 0.8902 mL | 1.7804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
